Validation Study on RENEW's Aingeal at KK Women's and Children's Hospital

NAActive, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

May 5, 2019

Study Completion Date

December 31, 2025

Conditions
Vital SignHeart RateRespiratory Rate
Interventions
DEVICE

Vital sign monitoring

Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.

Trial Locations (1)

229899

KK Women's and Children's Hospital, Singapore

All Listed Sponsors
collaborator

Renew Group

INDUSTRY

lead

KK Women's and Children's Hospital

OTHER_GOV

NCT03750318 - Validation Study on RENEW's Aingeal at KK Women's and Children's Hospital | Biotech Hunter | Biotech Hunter